Julien Seneschal

Julien Seneschal's picture
Professor of Dermatology
University Hospital of Bordeaux

Clinical Saturday Lecture

Date: Saturday 30 September 2017
Time: 13.10-13.40
Room: Europa Hall

Lecture Title: Vitiligo: From Pathogenesis to New Therapeutic Targets

Julien Seneschal is Professor of Dermatology at the University Hospital of Bordeaux, France, National Reference Center for Rare Skin disorders. His research career started in immunology in Bordeaux, where he studied the innate immune response and the role of activated platelets in the promotion of Type I Interferon (IFN) response in systemic lupus disease. During his post-doctoral fellowship at the Harvard Skin Disease Research Center (Boston, USA) under the direction of Professor Thomas Kupper, he was at the core of a research program dedicated to the newly described population of antigen experienced T cells known as Resident Memory T cells (TRM). He discovered that at steady state and in the absence of inflammation, epidermal Langerhans Cells (LC) appear to constitutively activate skin resident regulatory T cells, while when inflammation and antigen are present, LC can activate skin effector TRM. He then created with his colleague Dr Katia Boniface, the immuno-dermatology laboratory in Bordeaux, INSERM U1035, supported by the ATIP-AVENIR program. His research is now focused on understanding the immune pathomechanisms involved in the process leading to melanocyte loss in Vitiligo as well as depigmentation associated with inflammation or the use of immune-checkpoints therapies. He identified the role of type I IFN in the initiation of the immune response in Vitiligo and the impact of excessive production of the molecular chaperone HSP70 in the enhancement of this response, leading to the release of chemokines ligands (CXCL9 and CXCL10) important for the recruitment of CXCR3+ CD8 T Cells. His team is characterizing the phenotype and function of TRM in vitiligo and their role in the loss of melanocytes. The goal is to define new therapeutic targets in vitiligo for the development of more effective treatments to improve this disabling condition with high unmet needs. 

Website link: http://u1035-inserm.fr

Selected publications

C. Jacquemin, J. Rambert, S. Guillet, D. Thiolat, N Boukhedouni, MS Doutre, AS Darrigade, K Ezzedine, P. Blanco, A. Taieb, K. Boniface*, J Seneschal*. HSP70 potentiates interferon-alpha production by plasamcytoid dendritic cells : relevance for cutaneous lupus and vitiligo pathogenesis. Br J Dermatol 2017 *equal contribution 

M. Larsabal, A. Marti, C. Jacquemin, J. Rambert, D. Thiolat, L. Dousset, A. Taieb, C. Dutriaux, S. Prey, K. Boniface*, J. Seneschal*. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo”. J Am Acad Dermatol 2017  *equal contribution 

K. Boniface, A. Taïeb, J. Seneschal. New insights into immune mechanisms of vitiligo. G Ital Dermatol Venereol. 2015:151(1):44-54

C. Jacquemin*, N. Schmitt*, C. Contin-Bordes*, Y. Liu, P. Narayanan, J. Seneschal, T. Maurouard, D. Dougall, E. Spence Davizon, H. Dumortier, I. Douchet, L. Raffray, C. Richez, E. Lazaro, P. Duffau, M.E. Truchetet, L. Khoryati, P. Mercié, L. Couzi, P. Merville, T. Schaeverbeke, J.F. Viallard, J.L. Pellegrin, J.F. Moreau, S. Muller, R.L. Coffman, V. Pascual, H. Ueno* and P. Blanco*. OX40 Ligand Contributes to the Pathogenesis of Autoimmunity by Promoting T follicular Helper Response. Immunity, 2015: 1159-70 *equal contribution 

A.Bertolotti, K.Boniface, B.Vergier, M.D.Mossalayi, A.Taieb, K.Ezzedine, J.Seneschal: Type I Interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanom Res. 2014; 27: 398-407

J.Seneschal, X.Jiang, T.S. Kupper. Langerin+ Dermal DC, but Not Langerhans Cells, Are Required for Effective CD8-Mediated Immune Responses after Skin Scarification with Vaccinia Virus.  J Invest Dermatol. 2014; 134; 686-94

J.Seneschal, R.A.Clark, A. Gehad, Clare M. Baecher-Allan,  T.S. Kupper. Human Epidermal Langerhans Cells Maintain Immune Homeostasis in Skin by Activating Skin Resident Regulatory T Cells. Immunity, 2012: 873-84

P. Duffau*, J. Seneschal*, C.Nicco*, J.F.Viallard, J.L.Pellegrin, B.Weil, J.F.Moreau, F.Batteux*, P.Blanco*: Modulation of interferon-alpha secretion by activated platelets in systemic lupus erythematous.  Sci Transl Med. 2010; 47ra63 *equal contribution